NAT10 and gastric cancer: Consistent with the results of knocking down NAT10 using shRNA, our results showed that inhibiting NAT10 by treatment with Remodelin decreased the expression of VEGFA in human GC cells (Figure S3C, D), mouse tumor cells (MFCs) (Figure S3E, F), and human GC organoid models (Figure 2D, E)19.